Telix share price sinks 9% despite stellar half-year growth

This radiopharmaceuticals company delivered strong growth during the first half.

| More on:
Shot of a mature scientists working on a laptop in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is on the move on Friday morning.

At the time of writing, the ASX 200 healthcare stock is down 9% to $18.04.

This follows the release of its half-year results after the market close yesterday.

Telix share price sinks on half year results

  • Total group revenue up 65% to $364 million
  • Gross margin up to 66% from 63%
  • Adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) up 66% to $57.5 million
  • Net profit after tax of $29.7 million (up from a loss of $14.3 million)
  • FY 2024 guidance reaffirmed

What happened during the half?

For the six months ended 30 June, the ASX 200 healthcare stock reported a 65% increase in revenue to $364 million. This reflects continued growth in sales of its prostate cancer imaging agent Illuccix in the United States, which is now in its second full year of commercial sales.

Telix's gross margin improved to 66% (from 63%) due to the stable selling price of Illuccix and disciplined cost control.

This ultimately led to the company delivering a half-year net profit after tax of $29.7 million. This compares favourably to a loss of $14.3 million in the prior corresponding period.

Management commentary

The ASX 200 healthcare stock's managing director and CEO, Dr Christian Behrenbruch, was pleased with the results. He said:

Telix continues to grow revenue from Illuccix, increase gross profit margin and manage costs effectively, while investing for future growth. Our achievements in the first half of 2024 have created value for shareholders and positioned the Company for success on multiple fronts.

Building on our commercial success with Illuccix, we are focused on expanding the near-term opportunity in precision medicine diagnostics with three new products planned for launch in 2025, subject to regulatory approval.

At the same time, new efficacy data from the ProstACT SELECT trial has reinforced the therapeutic potential of TLX591 – our Phase III asset for prostate cancer therapy, while we have a number of additional significant clinical milestones ahead across our therapeutic pipeline.

Outlook

Failing to give the Telix share price a lift today is news that management has reaffirmed its guidance for FY 2024.

It continues to guide to full-year 2024 revenue of US$490 million to US$510 million (A$745 million to A$776 million at current exchange rates). This represents a 48% to 54% increase on what was recorded in FY 2023.

Telix also confirmed that its previously advised guidance for research and development expenditure remains unchanged.

Dr Behrenbruch concludes:

We believe the radiopharmaceutical sector is at an inflection point and Telix has the proven commercial ability, clinical experience and balance sheet strength to advance our leading-edge theranostic pipeline.

With a proven revenue stream and a clear path to future business growth, Telix is positioned at the vanguard of this fast-growing field.

Should you invest $1,000 in Telstra Corporation Limited right now?

Before you buy Telstra Corporation Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Telstra Corporation Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Lines of codes and graphs in the background with woman looking at laptop trying to understand the data.
Earnings Results

Westpac share price sinks on half-year results miss

Let's see how the big four bank performed during the first half.

Read more »

Miner looking at a tablet.
Gold

Newmont share price lifts off on first-quarter results

The ASX 200 gold stock is charging higher on Thursday.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Financial Shares

Up 53% in a year, why is this ASX 200 financial stock leaping higher again today?

Investors are sending the ASX 200 financial stock soaring on Wednesday. Let’s see why.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Why is this ASX 200 uranium stock rocketing 17% on Wednesday?

The ASX 200 uranium stock is racing higher today. But why?

Read more »

Piggy bank at the end of a winding road.
Dividend Investing

Why this $44 billion ASX 200 dividend stock is pushing higher today

The ASX 200 dividend stock trades on a yield of 4.6%.

Read more »

Workers inspecting a gas pipeline.
Energy Shares

Why is the Santos share price racing ahead of the ASX 200 today?

Santos shares are enjoying a day of strong outperformance. But why?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Financial Shares

What's happening with the AMP share price on Thursday?

A lot of AMP shares are changing hands on Thursday. But at what price?

Read more »